Enter your search terms:

MonoSol Rx to Present at 2015 American Association of Pharmaceutical Scientists Annual Exposition Demonstrating PharmFilm as a Bioequivalent Delivery Platform for Sildenafil Citrate

Company to Present Abstract Poster of Human Pilot Study Supporting PharmFilm® Bioavailability

Warren, N.J., October 21, 2015 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to develop treatments that improve patient outcomes and address unmet needs, today announced that the Company will present a poster supporting MonoSol Rx’s PharmFilm® oral soluble film as a bioequivalent delivery method of Sildenafil Citrate (Viagra) at the 2015 AAPS Annual Meeting and Exposition in Orlando, Fl., October 25-29.

The author will present a data poster supporting findings from a pilot human clinical trial. The trial compared two formulations of Sildenafil Citrate as an oral soluble film (OSF) against the traditional tablet form.

Logistical details are listed below:

  • Abstract M1196: “Bioequivalence of Two Formulations of Sildenafil Oral Soluble Film 100 mg and Sildenafil Citrate (VIAGRA) 100 mg Oral Tables in Healthy Male Volunteers”
  • Date: October 26, 2015
  • Location: Exhibit Hall WB1-WB2

Keith Kendall, CEO of MonoSol Rx, commented “By providing patients an attractive alternative to everyday drugs using PharmFilm technology, we further demonstrate that MonoSol Rx is a specialty pharmaceutical company whose products are at the forefront of research, development, and innovation.”

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx’s leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.

Latest comments

Sorry, the comment form is closed at this time.